secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K/A
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0000950170-24-097741
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q2 net loss $25M; cash $426.7M; NKX019 autoimmune trial Ntrust-2 to start by year-end
--------------------------------------------------------------------------------

- Net loss of $25.0M ($0.34 diluted EPS); R&D expense $23.1M, G&A $7.6M.
- Cash & investments $426.7M expected to fund operations into late 2027.
- FDA cleared second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment for systemic sclerosis, myositis, vasculitis expected by year-end 2024.
- Preliminary Ntrust-1 and Ntrust-2 data planned for 2025; NHL 7-day dosing cohort enrollment completed, data due late 2024.
- Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024097741/0000950170-24-097741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024097741/nktx-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-097741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer